Discover how spermidine supports autophagy, brain health, and cellular aging, plus research-backed benefits, safety, and how to use it in 2025.
I recently read “A Brief History of Intelligence” by Max Bennett — and I highly recommend you check it out — it’s an absolutely brilliant book! I will be having a few conversations with Max but for now here is a taster from our first chat about how our brain works like a simulation machine. You can buy his book from Amazon — https://amzn.to/3weN3uS Watch behind the scenes, get early access and join the private Discord by supporting us on Patreon. We have some amazing content going up there with Kenneth Stanley this week! Listen to this entire conversation now (Simulations chapter) on Patreon: / max-bennett-of-1–97975425 Watch part 2 (Mentalizing chapter) on Patreon —
/ max-bennett-of-2–98181787 Watch part 3 (Language) here
/ max-bennett-3–0-100006225
/ mlst (public discord)
/ discord
/ mlstreettalk.
Discover the world of neural dust as a new frontier in biomedical technology, promising to revolutionize healthcare by enabling real-time brain monitoring an…
Researchers at Washington University School of Medicine in St. Louis, along with collaborators at Northwestern University, have developed a noninvasive approach to treat one of the most aggressive and deadly brain cancers. Their technology uses precisely engineered structures assembled from nano-size materials to deliver potent tumor-fighting medicine to the brain through nasal drops. The novel delivery method is less invasive than similar treatments in development and was shown in mice to effectively treat glioblastoma by boosting the brain’s immune response.
Long-term adaptive deep brain stimulation (aDBS) provided tolerable, effective, and safe therapy in persons with Parkinson disease whose symptoms were previously stable while receiving continuous DBS.
Question Is long-term adaptive deep brain stimulation (aDBS) tolerable and as effective and safe as continuous DBS (cDBS)?
Findings In this nonrandomized clinical trial with an open-label comparison between cDBS and aDBS, the primary outcome was met as the majority of participants receiving aDBS achieved a performance goal of good on-time (ie, time when symptoms were well controlled) without troublesome dyskinesia relative to stable cDBS therapy.
Meaning Long-term aDBS provided tolerable, effective, and safe therapy in persons with Parkinson disease whose symptoms were previously stable while receiving cDBS.
Xie et al. demonstrate that systemic inflammation activates a subset of glutamatergic neurons in the ventrolateral periaqueductal gray (vlPAG). Manipulating these vlPAG glutamatergic neurons and their projections to the nucleus tractus solitarius modulates inflammation-induced sickness behaviors and hypometabolic states, including hypothermia, cardiovascular depression, reduced locomotion, and appetite suppression.
Dr. James Giordano, Chief of the Neuroethics Studies Program and Scholar-in-Residence in the Pellegrino Center for Clinical Bioethics at Georgetown University, speaks to cadets and faculty about how advancements in neuroscience and neurotechnology will impact the future of war. This event was hosted by the Modern War Institute at West Point.